Content

Sermorelin vs HGH: What Is the Difference?

Creator: Nadia Okonjo, Health Writer
Published: 2026-08-12

Sermorelin is a synthetic copy of the first 29 amino acids of growth-hormone-releasing hormone — a fragment that keeps the full GH-releasing activity of the 44-amino-acid original — while HGH therapy injects the finished hormone itself.

Nadia Okonjo, Health Writer August 12, 2026 8 min read

A woman holds a warm cup of tea in a sunlit kitchen, looking toward the window at the start of an unhurried morning

The short version

Sermorelin is a synthetic peptide made of the first 29 amino acids of growth-hormone-releasing hormone (GHRH). That fragment carries the full GH-releasing activity of the complete 44-amino-acid hormone.
HGH therapy delivers growth hormone itself. Sermorelin instead prompts the pituitary to release the body's own growth hormone in its natural pulsatile pattern.
Supplying growth hormone from outside suppresses the body's own production through negative feedback. Sermorelin works upstream of that loop, so its response stays capped by the body's own controls — somatostatin and IGF-1.
Compounded sermorelin is not FDA-approved, distinct from the FDA-approved product it once was: Geref, discontinued by its manufacturer in 2008 for reasons FDA later determined were not related to safety or effectiveness.
Both are prescription medicines in the United States. Which one — if either — fits a given patient is a clinical decision, not a shopping decision.

Sermorelin and injectable human growth hormone (HGH) act on the same hormonal axis from opposite directions, and nearly everything in the sermorelin vs HGH comparison follows from that. Sermorelin signals the pituitary gland to make and release the body's own growth hormone, in the pulses the gland already uses. HGH therapy skips the gland and supplies the finished hormone directly. The practical differences — what happens to your own production, what a blood test shows, how each is regulated — all trace back to who is producing the growth hormone and whether the body's feedback system stays in charge.

Neither is an over-the-counter product, and neither is a casual choice. This article lays out how each one works, why the feedback loop treats them differently, how sermorelin's regulatory history ended up where it is, and what a prescriber weighs between them.

What sermorelin is

Sermorelin is a synthetic peptide consisting of the first 29 amino acids of growth-hormone-releasing hormone (GHRH), the hypothalamic hormone that tells the pituitary gland to release growth hormone. Full-length GHRH runs 44 amino acids; the 1–29 fragment is the shortest piece that retains the parent hormone's full GH-releasing activity.

That structural fact is the whole design. GHRH's biological "message" lives in its first 29 residues, so a copy of just that segment — formally GHRH(1-29) — behaves at the receptor like the complete hormone while being a shorter chain that is simpler to manufacture. Sermorelin binds GHRH receptors on the somatotroph cells of the anterior pituitary, the cells whose job is producing growth hormone, and stimulates them to both make and release it. The growth hormone that results is the body's own, secreted by the body's own gland.

This is not a new molecule. GHRH-analog research dates to the mid-1980s, and sermorelin itself spent years as a clinical product: Prakash and Goa's 1999 review in BioDrugs covers its use in diagnosing and treating growth hormone deficiency in children, at a time when it was a marketed pharmaceutical rather than a compounded preparation.

What HGH therapy is

HGH therapy administers growth hormone itself — somatropin, a manufactured version of the human growth hormone molecule — by injection. Nothing is asked of the pituitary: the hormone arrives in circulation ready-made, in the amount injected, on the schedule injected, regardless of what the gland or its feedback controls are doing.

Somatropin is a prescription drug used for specific diagnosed conditions, classically growth hormone deficiency. Its defining feature for this comparison is directness. Because the hormone comes from outside, the amount in circulation is set by the dose rather than by the pituitary's own rhythm — and the body notices. Growth hormone administered from outside suppresses the body's endogenous GH production: the axis detects that levels are high and stops issuing its own supply. That suppression is standard endocrine feedback, the same reason many hormone-replacement approaches quiet the gland they replace.

How the feedback loop separates them

The growth hormone axis is self-limiting. Somatostatin inhibits GH release from above, and IGF-1 — the downstream effector growth hormone produces — feeds back to restrain it from below. Sermorelin acts upstream of both controls, so its effect stays inside the loop. Injected HGH enters below the loop, and the loop responds by shutting down native output.

This is the deepest difference between the two, and it cuts both ways. Because sermorelin only asks the pituitary to secrete, the response is capped: somatostatin and IGF-1 feedback limit how far any dose can push the axis, and the release that does occur keeps the natural pulsatile pattern — bursts, not a steady elevation. The pituitary stays in use, and the brakes stay connected. Walker's 2006 review in Clinical Interventions in Aging makes exactly this argument for GHRH-analog approaches in adult growth hormone insufficiency: stimulate the axis and its feedback stays intact, rather than replacing its product and overriding the loop.

Exogenous growth hormone has no such ceiling. The dose determines the exposure, feedback or not — which is precisely why it suppresses the body's own production, and why its use is confined to diagnosed deficiency states under specialist supervision.

Sermorelin vs HGH at a glance

The comparison reduces to a small table. Sermorelin is a signal — a fragment of the body's own releasing hormone that works through the pituitary and remains subject to its feedback. HGH is the hormone — supplied directly, bypassing the gland, suppressing native production, and regulated as a conventional pharmaceutical for diagnosed conditions.

	Sermorelin	Injectable HGH (somatropin)
What it is	Synthetic 29-amino-acid fragment of GHRH — GHRH(1-29)	The growth hormone molecule itself, manufactured as somatropin
Where it acts	GHRH receptors on somatotroph cells of the anterior pituitary	Enters circulation directly; the pituitary is bypassed
Source of the GH	Your own pituitary	The vial
Release pattern	Pulsatile — the gland's natural rhythm is preserved	Set by the dose and schedule, not the gland
Effect on your own production	Stays under somatostatin and IGF-1 feedback	Suppresses endogenous GH production via negative feedback
Regulatory status	Compounded by a licensed U.S. pharmacy; not FDA-approved (the former product Geref was discontinued in 2008)	Prescription somatropin brands remain on the market for specific diagnosed conditions
How it is obtained	Prescription only, after a provider review	Prescription only, for diagnosed indications

Where Geref fits in sermorelin's history

Today's compounded sermorelin is not FDA-approved, but the molecule itself once was: as Geref, sermorelin acetate entered the U.S. market in 1990 as a diagnostic agent and in 1997 as a treatment for pediatric growth hormone deficiency. The manufacturer discontinued both products in 2008, for reasons FDA later formally determined were not about safety or effectiveness.

The paper trail is public. Geref's diagnostic form was first approved December 28, 1990 (NDA 19-863) and its treatment form September 26, 1997 (NDA 20-443), both held by EMD Serono. In 2008 EMD Serono notified FDA it was discontinuing both and requested withdrawal of the applications. In 2013, FDA published a formal determination — Federal Register document 2013-04827 — that the Geref products were not withdrawn from sale for reasons of safety or effectiveness, the finding FDA issues when a discontinuation was a business decision rather than a regulatory one.

That history is worth stating precisely, because it is easy to garble in both directions. Sermorelin is not an experimental molecule that never reached patients — it was a marketed, prescribed pharmaceutical for nearly two decades. And the sermorelin available now is not that product: it is prepared by compounding pharmacies, and compounded formulations are not FDA-approved. A licensed provider may still prescribe compounded sermorelin — that decision is between you and your doctor.

Where CJC-1295 and ipamorelin fit

Sermorelin is one member of a wider family of molecules that raise growth hormone by stimulation rather than replacement. They split into two classes by receptor: GHRH analogs (sermorelin, tesamorelin, CJC-1295), which act on the GHRH receptor, and growth hormone releasing peptides or GHRPs (ipamorelin, GHRP-2, GHRP-6, hexarelin), which act on a different receptor entirely.

The distinction matters because the term "growth hormone secretagogue" gets used loosely. In the broad sense it covers anything that provokes GH secretion, sermorelin included. In the strict pharmacological sense it refers to agonists of the growth hormone secretagogue receptor (GHS-R1a) — the ghrelin receptor — which is the receptor GHRPs use. Sermorelin does not bind that receptor; it binds the GHRH receptor. Two different doors into the same gland.

Two doors also mean the classes can be used together. In a study published in the Journal of Clinical Endocrinology and Metabolism, Bowers and colleagues showed in 1990 that a growth hormone releasing peptide stimulated GH release in normal men and acted synergistically with GHRH — the combination released more growth hormone than either agent alone. That receptor-level synergy is the rationale behind modern paired products that combine a GHRH analog with a GHRP.

A comparative literature exists across these compounds — GHRP-2, GHRP-6, ipamorelin, CJC-1295, hexarelin, and against growth hormone itself — mapping their distinct pharmacological profiles. Chemists have also modified the GHRH scaffold for longer action: CJC-1295 is a GHRH analog engineered for extended duration, and tesamorelin is a stabilized version of the full 44-amino-acid hormone. Sermorelin, the unmodified 1–29 fragment, is the closest to the native signal.

What blood tests can and can't show

Growth hormone is secreted in pulses, so a single random GH blood draw is close to uninformative: the number depends on where in the pulse cycle the needle happened to land, and timing relative to secretion is critical for capturing a peak. This is why clinicians typically follow IGF-1 instead.

The pulsatility that makes sermorelin physiologically interesting is the same property that makes raw GH levels hard to read. IGF-1 — which the liver produces in response to growth hormone — integrates GH exposure over time and holds far steadier in circulation, so it serves as the practical readout of axis activity. A provider evaluating whether the GH axis needs attention, or whether a therapy is doing anything, is usually looking at IGF-1 alongside symptoms and history, not chasing a hormone that spikes and vanishes by the hour. This is also a reason self-assessment is unreliable in this area: the relevant labs need ordering and interpreting in context.

How this decision gets made

Sermorelin and HGH sit on the same axis but answer different clinical questions, and neither is chosen from a menu. A licensed provider reviews every request; not everyone qualifies, and a provider may decline. That review is the actual decision point — everything above is context for the conversation, not a substitute for it.

In practice the evaluation looks like medicine, because it is: health history, current medications, symptoms, and usually labs — IGF-1 among them — read together. Diagnosed growth hormone deficiency points toward conventional endocrinology and its own treatment pathways. Where a provider concludes a secretagogue approach is appropriate, sermorelin is prescribed individually and prepared as a compounded medication by a licensed U.S. pharmacy. And a provider who thinks neither option fits will say so; a declined request is the system working as designed.

This article is for educational purposes only and is not medical advice, diagnosis, or treatment. Talk with a licensed healthcare provider about your own situation.

Common questions

Is sermorelin the same as HGH?

No. They are different molecules with different jobs. HGH is growth hormone itself; sermorelin is a 29-amino-acid fragment of GHRH, the hormone that instructs the pituitary to release growth hormone. Sermorelin prompts your gland to secrete its own GH — HGH therapy supplies the hormone from outside.

Is sermorelin FDA-approved?

No. Sermorelin was once sold as the FDA-approved product Geref, but the compounded sermorelin prescribed today is not FDA-approved. Geref's manufacturer discontinued it in 2008, and FDA determined in 2013 that it was not withdrawn for reasons of safety or effectiveness. A licensed provider may still prescribe compounded sermorelin — that decision is between you and your doctor.

Why was Geref taken off the market?

Its manufacturer, EMD Serono, discontinued the Geref products in 2008 and asked FDA to withdraw the drug applications. In 2013 FDA published a formal determination that Geref was not withdrawn from sale for reasons of safety or effectiveness — the finding reserved for discontinuations made on business rather than regulatory grounds.

Does sermorelin shut down my body's own growth hormone production?

Sermorelin works upstream — it stimulates the pituitary rather than replacing its output, and the response stays subject to somatostatin and IGF-1 feedback, so the gland's own machinery remains in use. That preserved-feedback argument is the core of Walker's 2006 review. Supplying growth hormone from outside, by contrast, suppresses endogenous production.

What is sermorelin made of?

Sermorelin is a synthetic peptide of 29 amino acids — an exact copy of the first 29 residues of growth-hormone-releasing hormone, written GHRH(1-29). Full-length GHRH is 44 amino acids, and structure-activity work established that the 1–29 fragment retains the complete molecule's full GH-releasing activity.

How is sermorelin different from CJC-1295 and ipamorelin?

They occupy different points in the same family. Sermorelin and CJC-1295 are both GHRH analogs — CJC-1295 is modified for longer action, sermorelin matches the native fragment. Ipamorelin is a GHRP that acts on the ghrelin receptor (GHS-R1a), a separate receptor system. Paired products combine one of each class.

Can sermorelin be combined with other peptides?

The two secretagogue classes act through different receptors, and Bowers' 1990 study in normal men found GHRH and a growth hormone releasing peptide acted synergistically — more GH released together than by either alone. Whether any combination makes sense for a given patient is a prescribing decision, not a general rule.

Do I need a prescription for sermorelin?

Yes. Sermorelin is a prescription medication in the United States, dispensed as a compounded preparation by a licensed U.S. pharmacy. There is no legitimate over-the-counter route; products sold without a prescription are outside the regulated pharmacy system entirely.

How should sermorelin be stored?

Peptides are temperature-sensitive. In general handling terms that means refrigeration at 2–8 °C short-term and −20 °C or below for long-term storage, protected from light and moisture, with reconstituted solution used promptly. For a prescribed product, follow the dispensing pharmacy's label — that instruction, not general chemistry, governs your vial.

How long has sermorelin been studied?

Decades. GHRH-analog research dates to the mid-1980s, when structure-activity studies identified the 1–29 fragment as the shortest fully active piece of the hormone. Sermorelin then spent the 1990s and 2000s as the marketed pharmaceutical Geref, used in children with growth hormone deficiency, before its 2008 discontinuation.

Is HGH stronger than sermorelin?

Stronger is the wrong frame. Injected growth hormone raises circulating levels by the amount dosed, feedback or not; sermorelin's effect is bounded by what the pituitary will release under somatostatin and IGF-1 control. Whether that ceiling reads as a limitation or a safeguard is a clinical judgment for a prescriber, made per patient.

Why do providers measure IGF-1 instead of growth hormone?

Because GH is secreted in pulses, a single GH measurement mostly reflects timing luck. IGF-1, produced by the liver in response to growth hormone, integrates exposure over time and is far steadier in blood — so it functions as the working gauge of growth hormone axis activity in clinical evaluation.